Print Page  |  Contact Us  |  Sign In  |  Register
News & Press: General News

Lipoprotein(a) Foundation Expands Global Scientific Advisory Board

Wednesday, June 15, 2016   (0 Comments)
Posted by: Sandra Tremulis
Share |

 

May 17, 2016 -  Lipoprotein(a) Foundation Expands Global Scientific Advisory Board

Advisory Board to Be Actively Involved in the First-Ever Prospective Patient Registry to Study Lp(a) in the U.S. with Recent Grant from NORD in Conjunction with FDA

SAN CARLOS, Calif.--()--The Lipoprotein(a) Foundation announced today that it has expanded its global Scientific Advisory Board (SAB) to 27 members. The Advisory Board, comprised of the world’s leading experts on Lipoprotein(a), a highly prevalent, independent, genetic risk factor for early cardiovascular disease, provides support to the Foundation’s mission of saving lives by increasing awareness, advocating for routine testing, and supporting research that will lead to a specific treatment for elevated Lipoprotein(a).

The Lipoprotein(a) Foundation Scientific Advisory Board includes the following third party scientists, lipidologists, cardiologists and healthcare professionals:    

  • Benoit Arsenault, Ph.D., Universite Laval
  • Christie M. Ballantyne, M.D., Baylor College of Medicine
  • W. Virgil Brown, M.D., Emory University
  • John Chapman, Ph.D., DSc, Pitie-Salpetriere Hospital
  • Robert Clarke, M.D., Oxford University
  • Tom Dayspring, M.D., True Health Diagnostics
  • Keith Ferdinand, M.D., Tulane University,
  • Steve Foley, M.D., Comprehensive Women’s Care
  • Henry Ginsberg, M.D., Columbia College of Physicians and Surgeons
  • Jemma Hopewell, Ph.D., University of Oxford
  • Terry Jacobson, M.D., Emory University
  • Marlys Koschinsky, Ph.D., Robarts Research Institute, Western University
  • Florian Kronenberg, M.D., Medical University of Innsbruck
  • Joe McConnell, Ph.D., Salveo Diagnostics
  • Catherine J. McNeal, M.D., Ph.D., Baylor Scott & White Health
  • Michele Meitus Snyder, M.D., Children’s National Medical Center
  • Patrick M. Moriarty, M.D., University of Kansas Hospital
  • Pamela Morris, M.D., Medical University of South Carolina
  • Borge Nordestgaard, M.D., University of Copenhagen
  • Alan Remaley, M.D., Ph.D., National Heart, Lung, Blood
  • Raul Santos, M.D., Ph.D., University of Sao Paulo
  • Suzanne Shugg, N.P., NJ Cardiology Associates
  • Sam Tsimikas, M.D., University of California
  • Marina Vernalis, D.O., Walter Reed National Military Medical Center
  • Annabelle Santos Volgman, M.D., Rush College of Medicine
  • Robert Wild, M.D., Ph.D., University of Oklahoma
  • Joseph Witztum, M.D., University of California

In breaking news, the latest issue of The Lancet includes a paper from Advisory Board member Børge G. Nordestgaard, MD, DMSc, of the University of Copenhagen, titled “High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.” The results suggest that high lipoprotein(a) concentrations and corresponding LPA risk genotypes represent novel risk factors for clinical familial hypercholesterolaemia. The authors conclude that all individuals with familial hypercholesterolaemia should have their lipoprotein(a) measured in order to identify those with the highest concentrations, and as a result, the highest risk of myocardial infarction.

The Foundation recently announced that it has received a grant from the National Organization of Orphan Diseases (NORD) in conjunction with the U.S. Food & Drug Administration (FDA), to create the first prospective patient registry to study Lp(a) in the United States by collecting Lp(a) patient histories for research purposes. Members of the Advisory Board will be actively involved in data collection and analysis for the patient registry.          

    





Community Search
Sign In
Login with LinkedIn
OR
Sign In securely
Latest News
Featured Members

 
809 Laurel Street
San Carlos, CA 94070
650/995.3242